Immunologic Factor
Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report
FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications
FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression
FDA to Reassess Checkpoint Inhibitors for Stomach Cancer Based on PD-L1 Expression
FDA, checkpoint inhibitors, stomach cancer, PD-L1 expression, Oncologic Drugs Advisory Committee
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
Merck’s Ebola Vaccine Demonstrates 84% Effectiveness in Real-World Setting During DRC Outbreak
Ebola vaccine, Merck, Ervebo, effectiveness, real-world analysis, DRC outbreak, vaccination, public health.
FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer
Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs
Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti